K-ras 4A and 4B are co-expressed widely in human tissues, and their ratio is altered in sporadic colorectal cancer.

Ras activating mutations result in constitutive activation of Ras signalling pathways and occur in 30% of human malignancies. K-ras encodes two splice variants, K-ras 4A and 4B, and K-ras activating mutations which jointly affect both isoforms are prevalent in lung, pancreatic and colorectal cancers. Using RT-PCR we examined their expression in normal adult human tissues and addressed whether K-ras splicing is altered in sporadic colorectal cancer by comparing normal colon with colon carcinoma cell lines, and 'matched' tumour and tumour-free colon tissues from the same patient. K-ras 4B was expressed ubiquitously and was the predominant splice variant. K-ras 4A was expressed differentially, with detection in colorectal tumours and cell lines, and normal colon, pancreas and lung--sites where tumours with K-ras activating mutations arise. Both K-ras splice variants were co-expressed by single colon carcinoma cells. The K-ras 4A/4B ratio was significantly reduced in all 6 cell lines examined, including two that lacked K-ras activating mutations, and in 4/9 primary adenocarcinomas. We conclude that K-ras activating mutations do not affect K-ras splicing per se, both isoforms may play a role in neoplastic progression, and altered splicing of either the K-ras proto-oncogene or oncogene, in favour of K-ras 4B, may modulate tumour development.

[1]  I. B. Borel Rinkes,et al.  Control of colorectal metastasis formation by K-Ras. , 2005, Biochimica et biophysica acta.

[2]  L. Hesson,et al.  CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations , 2005, Oncogene.

[3]  D. Chung,et al.  Oncogenic K-ras stimulates Wnt signaling in colon cancer through inhibition of GSK-3beta. , 2005, Gastroenterology.

[4]  Mei Han,et al.  Matrix metalloproteinase-2 and tissue inhibitor of metallo-proteinase-2 in colorectal carcinoma invasion and metastasis. , 2005, World journal of gastroenterology.

[5]  Carmine Vecchione,et al.  Replacement of K‐Ras with H‐Ras supports normal embryonic development despite inducing cardiovascular pathology in adult mice , 2005, EMBO reports.

[6]  Lorena Losi,et al.  Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. , 2005, Carcinogenesis.

[7]  G Smith,et al.  The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma , 2005, Gut.

[8]  M. Yashiro,et al.  A novel high‐specificity approach for colorectal neoplasia: Detection of K‐ras2 oncogene mutation in normal mucosa , 2005, International journal of cancer.

[9]  W. Kolch,et al.  Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells. , 2005, Cancer research.

[10]  J. Venables.  Aberrant and Alternative Splicing in Cancer , 2004, Cancer Research.

[11]  W. Yoon,et al.  Gabexate Mesilate Inhibits Colon Cancer Growth, Invasion, and Metastasis by Reducing Matrix Metalloproteinases and Angiogenesis , 2004, Clinical Cancer Research.

[12]  I. Weissman,et al.  Therapeutic implications of cancer stem cells. , 2004, Current opinion in genetics & development.

[13]  M. Lai,et al.  Aberrant crypt foci as microscopic precursors of colorectal cancer. , 2003, World journal of gastroenterology.

[14]  Channing J Der,et al.  The dark side of Ras: regulation of apoptosis , 2003, Oncogene.

[15]  D. Harrison,et al.  While K-ras Is Essential for MouseDevelopment, Expression of the K-ras 4A Splice VariantIsDispensable , 2003, Molecular and Cellular Biology.

[16]  S. Fagan,et al.  Serum response factor is alternatively spliced in human colon cancer. , 2003, The Journal of surgical research.

[17]  M. Arends,et al.  K-ras proto-oncogene exhibits tumor suppressor activity as its absence promotes tumorigenesis in murine teratomas. , 2003, Molecular cancer research : MCR.

[18]  A. Wolfman,et al.  K-Ras Regulates the Steady-state Expression of Matrix Metalloproteinase 2 in Fibroblasts* , 2003, Journal of Biological Chemistry.

[19]  J. Schrader,et al.  Ras and relatives--job sharing and networking keep an old family together. , 2002, Experimental hematology.

[20]  Austin G Smith,et al.  Signalling, cell cycle and pluripotency in embryonic stem cells. , 2002, Trends in cell biology.

[21]  K. Cohn,et al.  Balance Between Activation and Inhibition of Matrix Metalloproteinase-2 (MMP-2) Is Altered in Colorectal Tumors Compared to Normal Colonic Epithelium , 2002, Digestive Diseases and Sciences.

[22]  Thierry Soussi,et al.  Targeted expression of oncogenic K-ras in intestinal epithelium causes spontaneous tumorigenesis in mice. , 2002, Gastroenterology.

[23]  M. Malumbres,et al.  The N-ras proto-oncogene can suppress the malignant phenotype in the presence or absence of its oncogene. , 2002, Cancer research.

[24]  H. Varmus,et al.  Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. , 2001, Genes & development.

[25]  A. Scorilas,et al.  Expression of Gelatinase-A (MMP-2) in Human Colon Cancer and Normal Colon Mucosa , 2001, Tumor Biology.

[26]  E. Livingston,et al.  Alternative mRNA splicing in colon cancer causes loss of expression of neural cell adhesion molecule. , 2001, Surgery.

[27]  Ming You,et al.  Wildtype Kras2 can inhibit lung carcinogenesis in mice , 2001, Nature Genetics.

[28]  A. Duval,et al.  Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines , 2001, Oncogene.

[29]  M. You,et al.  Alternative splicing of the K-ras gene in mouse tissues and cell lines. , 2001, Experimental lung research.

[30]  T. Hibi,et al.  Suppression of colorectal cancer growth using an adenovirus vector expressing an antisense K-ras RNA. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[31]  J. G. Park,et al.  Novel transcripts of fibroblast growth factor receptor 3 reveal aberrant splicing and activation of cryptic splice sequences in colorectal cancer. , 2000, Cancer research.

[32]  R. Klemke,et al.  Four Human Ras Homologs Differ in Their Abilities to Activate Raf-1, Induce Transformation, and Stimulate Cell Motility* , 1999, The Journal of Biological Chemistry.

[33]  C. Ghigna,et al.  Altered expression of heterogenous nuclear ribonucleoproteins and SR factors in human colon adenocarcinomas. , 1998, Cancer research.

[34]  N. Hawkins,et al.  Developmentally-regulated expression of murine K-ras isoforms , 1997, Oncogene.

[35]  R. Kucherlapati,et al.  K-ras is an essential gene in the mouse with partial functional overlap with N-ras. , 1997, Genes & development.

[36]  J. Weissfeld,et al.  K-ras gene mutations in normal colorectal tissues from K-ras mutation-positive colorectal cancer patients. , 1997, Cancer research.

[37]  J. Hardcastle,et al.  Ki‐ras MUTATIONS IN ADENOMAS: A CHARACTERISTIC OF CANCER‐BEARING COLORECTAL MUCOSA , 1996, The Journal of pathology.

[38]  P. Seeburg,et al.  Activation of Ki-ras2 gene in human colon and lung carcinomas by two different point mutations , 1983, Nature.

[39]  E. Chen,et al.  Structure and organization of the human Ki-ras proto-oncogene and a related processed pseudogene , 1983, Nature.

[40]  D. Harrison,et al.  The K-Ras 4A isoform promotes apoptosis but does not affect either lifespan or spontaneous tumor incidence in aging mice. , 2006, Experimental cell research.

[41]  J. Edwards,et al.  Detecting Changes in the Relative Expression of KRAS2 Splice Variants Using Polymerase Colonies , 2004, Biotechnology progress.

[42]  R. Kole,et al.  RNA modulation, repair and remodeling by splice switching oligonucleotides. , 2004, Acta biochimica Polonica.

[43]  S. Markowitz,et al.  Genetic and epigenetic alterations in colon cancer. , 2002, Annual review of genomics and human genetics.